Trials / Completed
CompletedNCT05712889
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Vincerx Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
Detailed description
Solid tumor subjects with histologically confirmed advanced or metastatic disease who have relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIP236 (Q3W) | VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle. |
| DRUG | VIP236 (Q2W) | VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle. |
Timeline
- Start date
- 2023-01-24
- Primary completion
- 2024-10-10
- Completion
- 2024-10-10
- First posted
- 2023-02-06
- Last updated
- 2024-11-15
Locations
6 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05712889. Inclusion in this directory is not an endorsement.